LexaGene Life Sciences

LexaGene Life Sciences

Closed: Oct. 2024

About this raise

LexaGene Life Sciences is raising funds on Dealmaker Securities. The company is pioneering the technology that provides timely and automated detection of pathogen and bacterial contaminants. LexaGene Life Sciences’ system, MiQLab, is about 300 times faster than the conventional methods and can tap into both biopharma production and veterinary diagnostics. The system is highly accurate and can give results in two hours compared to the 28 days of older methods. Dr. Jack Regan founded LexaGene Life Sciences in August 2023. The current crowdfunding campaign has a minimum target of $25,750 and a maximum target of $5 million. The campaign proceeds will be used for enhancements to the system, hiring, and marketing.

Expand

Investment Overview

Not Funded: $0

Deal Terms

Total Commitments

Platform
DealMaker Securities
Start Date
11/01/2023
Close Date
10/31/2024
Min. Goal
$25,750
Max Goal
$5,000,000
Min. Investment

$1,030

Security Type

Equity - Common

Company Stage

Early Stage

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$1.03

Company & Team

Company

Year Founded
2023
Industry
Healthcare & Pharmaceuticals
Tech Sector
HealthTech
Distribution Model
B2B
Margin
Medium
Capital Intensity
High
Location
Dallas, Texas
Business Type
Growth
Company Website
Visit Website

Team

Employees
5
Prior Founder Exits?
No
Founder Name
Jack Regan
Title
CTO

Funding data not publicly available

Financials

 Revenue
$0
as of FY2022
 Cash on Hand
$1,000
as of FY2022

Summary Profit and Loss Statement

FY 2022 FY 2021

Revenue

$0

$0

COGS

$11,433

$0

Tax

$0

$0

 

 

Net Income

$11,433

$0

Summary Balance Sheet

FY 2022 FY 2021

Cash

$1,000

$0

Accounts Receivable

$0

$0

Total Assets

$64,620

$0

Short-Term Debt

$0

$0

Long-Term Debt

$0

$0

Total Liabilities

$0

$0

Create a free account today to gain access to Kingscrowd analytics and financials.

Upgrade to gain access

Pay Monthly
Annually (2 months free)

Edge

$12.50 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific Kingscrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Company Funding & Growth

Funding history

Total Prior Capital Raised
$0
VC Backed?
No
Close Date Platform Valuation Total Raised Security Type Status Reg Type
10/31/2024 DealMaker Securities - $0 Equity - Common Not Funded RegCF
Create a free account today to gain access to Kingscrowd analytics.
Founders: enhance your startup's credibility on Kingscrowd. Create an account to claim this raise page.
Add to portfolio
LexaGene Life Sciences on Dealmaker Securities 2023
Platform: DealMaker Securities
Security Type: Equity - Common
Price per Share: $1.03

Follow company

Follow LexaGene Life Sciences on Dealmaker Securities 2023

Buy LexaGene Life Sciences's Deal Report

Warning: according to the close date for this deal, LexaGene Life Sciences may no longer be accepting investments.

LexaGene Life Sciences Deal Report

Get Kingscrowd's comprehensive report on LexaGene Life Sciences including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether LexaGene Life Sciences is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the LexaGene Life Sciences deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge